n Cardiovascular Journal of South Africa - ARBITER-2 : evidence that targeting HDL cholesterol slows atherosclerosis : drug trends in cardiology

Abstract

Extracted from text ... Addition of a prolonged-release nicotinic acid (not yet available in SA) to statin therapy arrested progression of atherosclerosis among coronary heart disease (CHD) patients with low levels of highdensity lipoprotein (HDL) cholesterol in the ARBITER-2 study.1 Prof. Derick Raal, Head of the Division of Endocrinology and Metabolism, Department of Medicine, Johannes burg Hospital, noted at a special media briefing in Johannesburg that this means that nicotinic acid is currently the most potent drug available to physicians to raise HDL cholesterol. The ARBITER-2 (ARterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol) study included 167 patients with known ..